Sponsor:
UCLA
Code:
NCT06028828
Conditions
Allogeneic Hematopoietic Stem Cell Transplantation
Allogeneic Stem Cell Transplantation
Hematologic Malignancies
Eligibility Criteria
Sex: All
Age: 18 - 70
Healthy Volunteers: Not accepted
Interventions
Fludarabine
Melphalan
Total Body Irradiation
Brief summary:
Conditions
Allogeneic Hematopoietic Stem Cell Transplantation
Allogeneic Stem Cell Transplantation
Hematologic Malignancies
Study ID
NCT06028828
Start date
Sep 11, 2023
Status verified date
Jan, 2026
Completion date
Sep, 2027
Anticipated
Primary completion date
Sep, 2026
Anticipated
Eligibility Criteria
Sex: All
Age: 18 - 70
Healthy Volunteers: Not accepted
Enrollment
60 participants
Anticipated
Intervention Model
Single group
Primary purpose
Treatment
Arms
experimental: Patients with AML, ALL, MDS, CML, NHL, HD, CLL requiring AHSCT
Interventions
Fludarabine
Melphalan
Total Body Irradiation
Primary outcome measure
Central contacts
Chao Family Comprehensive Cancer Center University of California, Irvine
1-877-827-8839ucstudy@uci.eduLocations
Chao Family Comprehensive Cancer Center, University of California Irvine
Recruiting
Orange, California, United States, 92868
Contacts
Sponsor
University of California, Irvine
Last update posted
Feb 2, 2026
Last verified
Jan, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of California, Irvine on 2026-02-02.